Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The loxP (locus of crossover in P1) DNA sequence is a 34-base pair site-specific recombination sequence originally identified in the bacteriophage P1 [1]. It is composed of two 13-base pair inverted repeat elements that serve as binding sites for Cre recombinase, separated by an 8-base pair asymmetric spacer region that provides directionality to the recombination event [2]. When two loxP sites are present in a genome, the Cre enzyme facilitates a precise recombination reaction that can result in the excision, inversion, or translocation of the DNA located between them, depending on their orientation [3]. While not a traditional endogenous therapeutic target, the Cre-loxP system is an essential tool in biomedical research for generating conditional knockout and knock-in mouse models, allowing scientists to study gene function with spatial and temporal specificity [4]. In the context of advanced therapeutics, loxP sequences are utilized in gene therapy vectors to enable the precise removal of selection markers or to control the expression of therapeutic transgenes [5]. However, the clinical application of this system faces challenges, including the potential for Cre-mediated toxicity due to recombination at endogenous pseudo-loxP sites in the human genome and the risk of an immune response against the non-human Cre protein [6].
Cre recombinase recognizes and binds to the 13-bp inverted repeats of two loxP sites, forming a synaptic complex where it catalyzes a reciprocal strand exchange and DNA cleavage/ligation, resulting in the excision, inversion, or translocation of the intervening DNA sequence depending on the relative orientation of the loxP sites [1, 2, 3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Locus of crossover in P1 (loxP) DNA sequence (loxP).